LONDON (Reuters) – 100 Scientists who gave fruit flies a triple drug combination treatment and found that it extended their lives by almost 50% say their work offers clues on how to fight aging in people.
FILE PHOTO: A fruit fly is seen in a laboratory at the Bar-Ilan University, in Ramat Gan, Israel, May 1, 2018. REUTERS/Amir Cohen
The researchers said their aim is not to find the secret of eternal life, but to figure out the mechanism of the aging process to find ways to help people stay healthy for longer.
(Reuters Health) – On-the-job exposure to high levels of pesticides might raise the risk of developing heart disease or having a stroke, according to a long-term study in Hawaii.
Farm and agricultural workers need to wear personal protective equipment and, even after they retire should continue to have their health monitored for cardiovascular complications, the authors conclude in the Journal of the American Heart Association.
“Pesticides have a long half-life and exist in the body for a long time, so side effects may appear even 10-20 years later,” said lead author Zara Berg of Fort Peck Community College in Peck, Montana.
Tuberculosis or TB is a highly contagious infection that usually affects the lungs, but it can spread to other parts of the body, such as the spine and brain. Commonly caused by Mycobacterium tuberculosis, which can spread through the air from person to person. A person doesn’t know he or she is sick, as the bacteria can live in the host for years, without causing symptoms.
3D illustration of bacterium Mycobacterium tuberculosis. Image Credit: Kateryna Kon / Shutterstock
DHAKA (Reuters) – Bangladesh’s drug regulatory authority on Sunday issued a ban on sales of popular heartburn drug ranitidine while it investigates a potential cancer-causing substance in the drug.
The move comes after the U.S. Food and Drug Administration (FDA) warned that some of the pills contained small amounts N-nitrosodimethylamine (NDMA), which the regulator says is a “probable human carcinogen”.
“We have banned the import of raw materials, production and sale of ranitidine until further notice,” said Khandaker Sagir Ahmed, a director of Bangladesh’s drug regulatory authority, adding that the decision was taken a precautionary measure.
FILE PHOTO: Logo of Swiss drugmaker Novartis is seen at its branch in Schweizerhalle near Basel, Switzerland, March 29, 2018. REUTERS/Arnd Wiegmann/File Photo
ZURICH (Reuters) – Novartis said on Sunday that Kisqali helped women with advanced breast cancer after menopause live longer, adding to data the Swiss company hopes will help convince doctors to choose its drug over Pfizer’s blockbuster Ibrance.
Kisqali plus the hormone therapy fulvestrant, when compared to fulvestrant alone, demonstrated a significant improvement in survival with a 28% reduction in risk of death, Novartis said at the European Society for Medical Oncology meeting in Barcelona.
Kaiser Health News is suing the U.S. Centers for Medicare & Medicaid Services to release dozens of audits that the agency says reveal hundreds of millions of dollars in overcharges by Medicare Advantage health plans.
The suit, filed late Thursday in U.S. District Court in San Francisco under the Freedom of Information Act, seeks copies of 90 government audits of Medicare Advantage health plans conducted for 2011, 2012 and 2013 but never made public. CMS officials have said they expect to collect $650 million in overpayments from the audits. Although the agency has disclosed the names of the health plans under scrutiny, it has not released any other details.
BARCELONA (Reuters) – GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian cancer patients, possibly helping GSK catch its rival in a highly contested drug class.
FILE PHOTO: The GlaxoSmithKline (GSK) logo is seen on top of GSK Asia House in Singapore, March 21, 2018. REUTERS/Loriene Perera/File Photo
The two said separately on Saturday their drug candidates – in a class known as PARP inhibitors – staved off the return of metastasized ovarian cancer in women who had responded to initial standard treatment, reducing the risk of a relapse.
(Reuters) – An experimental Amgen Inc drug that targets a specific genetic mutation shrank tumors in just one of 12 patients with advanced colorectal cancer who were given the highest dose in a small, early-stage trial, the company said on Saturday.
The cancer stopped growing in 10 of the patients taking 960 milligrams of AMG510 daily, while one patient had tumor progression, according to Phase I trial data presented in Barcelona at a meeting of the European Society of Medical Oncology (ESMO).
In addition, one of the 10 patients whose colon cancer had initially stabilized later left the trial after the disease worsened.